Working… Menu

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04057365
Recruitment Status : Recruiting
First Posted : August 15, 2019
Last Update Posted : January 26, 2021
Bristol-Myers Squibb
Leap Therapeutics, Inc.
Information provided by (Responsible Party):
Goyal, Lipika, Massachusetts General Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 31, 2022
Estimated Study Completion Date : August 31, 2024